Cerebral palsy results from non-progressive brain injury around the time of birth, producing motor dysfunction, spasticity and variable cognitive or sensory impairment. Stem-cell research targets neuroprotection and plasticity: placental mesenchymal stem cells are studied for anti-inflammatory effects that may limit secondary neuronal loss and reduce spasticity, while neurogenic cells are explored to support damaged motor circuitry and synaptic reorganisation. Because the brain injury is fixed, intervention aims to limit secondary damage and enhance plasticity rather than reverse established damage. Trials enrol children and young adults; reported outcomes include spasticity reduction and motor-function changes, usually alongside intensive physiotherapy.
Forty-one registered trials and 2 recruiting studies investigate stem-cell approaches in cerebral palsy, mostly in Asia and Latin America. Small cohorts describe reduced muscle tone and improved gross-motor scores within 3–12 months; most lack adequate controls or blinding. Placebo effects in rehabilitation are substantial, and concurrent physiotherapy confounds attribution. No large randomised trial has shown stem cells superior to intensive physiotherapy or established interventions; few studies follow beyond 12 months.
Indicative European costs are roughly €4,000–€7,500 per course. Paediatric infusions add safety monitoring and often use multiple small doses over weeks. Some protocols bundle intensive rehabilitation, adding further cost. For context, physiotherapy, botulinum toxin and orthopaedic surgery are established, often insurance-covered interventions — the stem-cell figure is indicative and unproven.
Cell therapy for Cerebral Palsy is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Cerebral Palsy programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка